SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cambridge Antibody Technology Group
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jongmans who started this subject1/20/2003 7:18:42 AM
From: nigel bates   of 625
 
Despite Humira, Abbott must still see mice as an option -
Message 18465607

Meanwhile, parking more on ribosome display:

IMPROVEMENTS TO RIBOSOME DISPLAY
Patent Number:  WO0175097 
Publication date: 2001-10-11 
Inventor(s): HOLET THOR (GB); OSBOURN JANE (GB) 
Applicant(s): CAMBRIDGE ANTIBODY TECH (GB); HOLET THOR (GB); OSBOURN JANE (GB) 
Requested Patent: EP1268766 
Application Number: WO2001GB01319 20010326 
Priority Number(s): US20000193802P 20000331 
IPC Classification: C12N15/10; C12Q1/68; C07K16/00 
EC Classification: C07K16/44, C12N7/04A, C07K16/00, C12N15/10C2 
Equivalents: AU3944401,  GB2365429 
Cited patent(s): WO9410329; WO9958661; WO9911777; WO9854312; WO9848008; WO9406920 
------------------------------------------------------------------------
Abstract
------------------------------------------------------------------------

The use in a ribosome display system for a selection of a specific binding pair member (e.g. antibody molecule) able to bind a complementary specific binding pair member (e.g. antigen) of encapsidating specific binding member/ribosome complexes ina viral coat, optionally in combination with incorporation of an Midvariant RNA template and optionally one or more other improvements selected from : glycine-serine tether, protein disulphide isomerase, protein disulphide isomerase in combination with oxidised and reduced glutathione at a ratio of between 1:1 and 10:1, addition of oxidised and reduced glutathione at a ratio of between 1:1 and 10:1 after 30 minutes of in vitro translation; blocking with heparin during selection.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News